Amgen (AMGN)

NetworkNewsWire Editorial Coverage : As the American population gets older, chronic and rare diseases are becoming a significant healthcare issue, particularly for older adults. The aging population’s increasing life expectancy also leads to more complex healthcare needs, especially for conditions that are both chronic and difficult to diagnose. Many of these rare conditions lack FDA-approved treatments, and their symptoms in seniors are frequently mistaken for normal signs of aging, causing diagnostic delays that can last for years. There are more than 30 million Americans who have a rare disease, so there is a growing need for accurate diagnoses and effective treatments. The Trump administration’s “Make America Healthy Again” initiatives have highlighted this problem and focused on improving access to treatments and speeding up medical innovation. Soligenix Inc. (NASDAQ: SNGX) ( Profile ) is working to advance this mission with its HyBryte(“TM”) platform, a new therapy for cutaneous T-cell lymphoma (“CTCL”), a rare form of skin cancer that largely impacts older adults. The company has successfully established U.S.-based manufacturing for HyBryte’s active ingredient, demonstrating the kind of domestic innovation that can significantly help this underserved patient group. Soligenix is one of several notable companies dedicated to making an impact in the pharmaceutical field, alongside Amgen Inc. (NASDAQ: AMGN), Amicus Therapeutics Inc. (NASDAQ: FOLD), Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) and…

EQNX::TICKER_START (NASDAQ:SNGX),(NASDAQ:FOLD),(NASDAQ:TNXP),(NASDAQ:CTOR),(NASDAQ:AMGN) EQNX::TICKER_END

NEW YORK, March 05, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Amgen Inc. (NASDAQ: AMGN) on behalf of long-term stockholders following a class action complaint that was filed against Amgen on March 13, 2023 with a Class Period from July 29, 2020 and April 27, 2022. Our investigation concerns whether the board of directors of Amgen have breached their fiduciary duties to the company.

NEW YORK, Nov. 15, 2024 (GLOBE NEWSWIRE) --  Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Amgen Inc. (NASDAQ: AMGN) on behalf of long-term stockholders following a class action complaint that was filed against Amgen on March 13, 2023 with a Class Period from July 29, 2020 and April 27, 2022. Our investigation concerns whether the board of directors of Amgen have breached their fiduciary duties to the company.

Eli Lilly and Co. (NYSE: LLY) is a pharmaceutical giant that's made headlines for its GLP-1/GIP weight loss drug Tirzepatide, aka Mounjaro, for Type 2 diabetes.

Stocks were looking for direction to end the week, but next week may bring more volatility with the latest reading on inflation and the start of retail earnings

Amgen's shares fell 2.4% after-hours trading due to a mixed earnings release. MariTide, the company's weight loss drug, is in Phase II FDA trials.

Following lower-than-expected inflation data on Thursday, The biotech sector broke out above resistance, closing the week up 6%, far outperforming the market.

IDEAYA Biosciences stock is up more than 16% on positive treatment data in a Phase 2 clinical trial, but after a 76% run-up, IDYA stock may need a breather

The biotech sector (IBB) is trading just 3% away from its 52-week high and a significant resistance level, suggesting a potential breakout.

EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:KYMR),(NASDAQ:GILD),(OTCQX:RHHBY),(NASDAQ:AMGN) EQNX::TICKER_END

PALM BEACH, Fla., June 20, 2024 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - Pancreatic cancer is among the most frequently diagnosed and the seventh leading cause of cancer death globally. Pancreatic cancer becomes more common in the Western world. The prevalence rate of pancreatic adenocarcinoma is expanding in the developed world, and adaptive lifestyle habits such as alcohol and obesity may play a critical role. A report from Future Market Insights projects that the global pancreatic cancer market is projected to accelerate at a CAGR of 13.5% to top US$ 7,541.09 Million by 2033. The report said: “Despite advances in surgical technique, chemotherapy treatments, and the emergence of neoadjuvant chemoradiotherapy, five-year survivorship from this ailment is as low as 2.5% in certain countries. The total number of reported cases of pancreatic cancer in the 7MM nations was around 175,770 in 2021, and this was predicted to increase market growth during the historical period. The upsurge of an unhealthy lifestyle and poor diet has heightened the number of individuals suffering from pancreatic diseases/conditions. The high incidence of diabetes patients has been mainly ascribed to the rising demand for packaged foods and beverages with elevated amounts of sugar, which also significantly contributes to the growing cases of pancreatic cancer patients. Thus, these factors will drive the market growth during the forecast period with a CAGR of 13.5%.” Active biotech and pharma companies in the markets this week include Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), Kymera Therapeutics, Inc. (NASDAQ: KYMR), Roche (OTCQX: RHHBY), Gilead Company (NASDAQ: GILD), Amgen (NASDAQ: AMGN).

Biotechnology firm Moderna Inc. (NASDAQ: MRNA) made mainstream headlines during the pandemic for its COVID-19 vaccines. Moderna is focused on messenger RNA

The Biotech sector ETF is consolidating in its upper range, indicating a potential sector breakout despite modest year-to-date gains

The booming weight loss drug market presents both lucrative potential and significant risks for investors seeking to capitalize on the global obesity crisis.

Overlooked, oversold large-cap stocks offer compelling dividend yields for investors seeking income and potential capital appreciation

Amazon replaced Walgreens in the Dow. While a positive move for Amazon, any impact on the stock's price may be limited due to low index weighting.

These three Dow laggards have suffered double-digit percentage declines this winter, contributing to the Dow’s underperformance versus other major averages.

The Dow hits record highs with IBM, Verizon, Merck, and insurer Travelers leading the way; those strong stocks don't make much of a dent in S&P performance

2024 holds promise for healthcare stocks, with Humana, Elevance, and others expected to boost earnings, as analysts say many industry pressures have been removed.

NetworkNewsWire Editorial Coverage : On Sept. 20, 2019, history was made when the U.S. Food and Drug Administration approved Rybelsus as the first oral glucagon-like peptide-1 (GLP-1) agonist for type 2 diabetes (T2D). However, it wasn’t just a milestone for T2D management. It was a turning point in medicine, opening the floodgates to a universe of potential therapeutic applications for this remarkable molecule. While undeniably transformative for diabetes and weight loss, GLP-1’s reach now extends far beyond, likely surpassing even the wildest dreams of its creators. From Alzheimer’s and Parkinson’s to drug addiction, clinical trials are painting a stunning picture of GLP-1’s versatility. And it doesn’t stop there. Strong evidence points to opportunities in heart disease, chronic kidney disease and a plethora of other conditions. The newfound applications of this super-drug re-enforce the significant potential for Lexaria Bioscience Corp. (NASDAQ: LEXX) ( Profile ), with its powerful DehydraTECH(TM) drug-delivery formulation and processing technology that improves both delivery and efficacy of GLP-1 for diabetes and potentially a host of other maladies. Lexaria joins other companies, including Amgen Inc. (NASDAQ: AMGN) , Eli Lilly and Company (NYSE: LLY) , Roche (OTCQX: RHHBY) and WW International Inc. (NASDAQ: WW) , that are committed to providing powerhouse solutions in the fields of diabetes, weight loss and more.

EQNX::TICKER_START (NASDAQ:LEXX),(NASDAQ:AMGN),(NYSE:LLY),(OTCQX:RHHBY),(NASDAQ:WW) EQNX::TICKER_END

With the bullish news flow lately, the market has taken a liking to health care stocks in recent weeks - including these three early 2024 gainers.

EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:AMGN),(NASDAQ:AMAM),(NASDAQ:ELEV),(NASDAQ:NKTX) EQNX::TICKER_END

PALM BEACH, Fla., Jan. 09, 2024 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - According to the report titled "Aging in the United States," published by the Population Reference Bureau, "the number of Americans aged 65 and older is projected to increase more than double over 95 million by the year 2060, and it is expected to rise to approximately 23 percent from 16 percent. Cancer is a non-treatable chronic disease that has posed a challenge to the medical fraternity for decades. The fatal nature of the disease, coupled with the low rate of success for treatments, has compelled medical practitioners to deploy new research methodologies. The entire medical research fraternity has prioritized cancer research in order to find new ways of treatment and analysis. According to Nova one advisor, the global Oncology Cancer Drugs market was valued at USD 147.2 billion in 2021 and it is expected to hit around USD 289.2 billion by 2030 with a CAGR of 8.4% during the forecast period 2022 to 2030. The report said: “Cancer drugs are utilized the treatment of pancreatic cancer, breast cancer, ovarian cancer, gastric cancer, kidney cancer, brain tumors, and other cancers through chemotherapy, surgery, and radiotherapy.”   Active biotech and pharma companies in the markets this week include Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), Amgen (NASDAQ: AMGN), Ambrx Biopharma, Inc., (NASDAQ: AMAM), Elevation Oncology, Inc. (NASDAQ: ELEV), Nkarta, Inc. (NASDAQ: NKTX).